In addition to clearing moderate to severe plaque psoriasis, secukinumab (Cosentyx, Novartis) has been shown to improve quality-of-life measures, including “mobility, self-care, and usual activities of daily living,” according to a presentation at the 2019 Annual Maui Derm for Dermatologists meeting.
JANUARY 28, 2019